BioCentury This Week
Episodes
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
30 Dec 2025
Contributed by Lukas
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, a...
Ep. 340 - Obesity Data, Kymera & FDA Survey Results
16 Dec 2025
Contributed by Lukas
Obesity readouts continue to be hot for biotech with new top-line data from both injectable and oral therapies pushing the boundaries on efficacy. On ...
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
09 Dec 2025
Contributed by Lukas
Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go ...
Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, C> Funding
02 Dec 2025
Contributed by Lukas
Novo Nordisk’s highly anticipated data for semaglutide in Alzheimer’s dashed hopes that the GLP-1 therapy could become a game changer in the disea...
Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc
25 Nov 2025
Contributed by Lukas
A baffling decision by FDA to issue a complete response letter for a pediatric medicine the medical community stood behind is just the latest example ...
Ep. 336 - Cautious Optimism and M&A Momentum
22 Nov 2025
Contributed by Lukas
There is cautious optimism around continued M&A momentum and the public equities markets as biotech heads into the New Year. On a special edition ...
Ep. 335 - Neurology's Coming Inflection Point
21 Nov 2025
Contributed by Lukas
Voyager CEO and former head of R&D at Biogen Al Sandrock is more optimistic than ever about the prospect of bringing clinically meaningful solutio...
Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi
18 Nov 2025
Contributed by Lukas
Richard Pazdur took the top job at FDA’s Center for Drug Evaluation and Research after receiving vows that he would be leading CDER free from politi...
Ep. 333 - Is This Korea’s Biotech Moment?
13 Nov 2025
Contributed by Lukas
Today’s South Korean biotechs have a risk-on mentality, a willingness to partner, and strategies focused on globalization. On a special edition of t...
Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA
11 Nov 2025
Contributed by Lukas
With ObesityWeek yielding eye-catching amylin data and a bidding war that ran to $10 billion for Metsera, weight loss companies were center stage in b...
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
04 Nov 2025
Contributed by Lukas
Novo Nordisk’s unsolicited $8.5 billion bid for Metsera has thrown a wrench into Pfizer’s plans to return to the obesity race via its acquisition ...
Ep. 330 - China's Innovation Moment
01 Nov 2025
Contributed by Lukas
China is setting a new bar for the speed of clinical development and redefining the time it takes an asset to get to the clinic. On a special edition ...
Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors
28 Oct 2025
Contributed by Lukas
Novartis’ biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On th...
Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers
21 Oct 2025
Contributed by Lukas
Next-generation platforms and technologies are getting closer to cracking one of biopharma’s biggest problems: delivering medicines, and mAbs in par...
Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg
16 Oct 2025
Contributed by Lukas
It’s been a tough year for cell and gene therapy — patient deaths, high-profile companies pulling out of the space, and sour investment sentiment....
Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A
14 Oct 2025
Contributed by Lukas
Biotech’s fourth quarter began with a familiar feeling, with indicators pointing toward an improving public market even as political and regulatory ...
Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund
07 Oct 2025
Contributed by Lukas
The short-term consequences for Pfizer from its “most favored nation” drug pricing deal with the White House are negligible, but the long-term eff...
Ep. 324 - Genmab, GSK and Drug Pricing
30 Sep 2025
Contributed by Lukas
Genmab's $8 billion acquisition of multispecifics company Merus is the Danish biotech’s largest step toward marketing its own pipeline. On the ...
Ep. 323 - Agentic AI: From New Targets to the Clinic
25 Sep 2025
Contributed by Lukas
AI is bringing sweeping changes to drug development, from how targets are discovered to optimizing clinical trials to maximize an asset’s chance for...
Ep. 322 - Takeaways from BioCentury Grand Rounds Europe
23 Sep 2025
Contributed by Lukas
Is this the U.K.’s moment to capitalize on its biotech ecosystem? That was one of the primary themes discussed at the debut Grand Rounds — Europe ...
Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus
23 Sep 2025
Contributed by Lukas
A takeout that could be worth as much as $7.3 billion has Pfizer back in the obesity drug development race. On the latest BioCentury This Week podcast...
Ep. 320 - U.K. Biotech, U.S.-China, Insmed
16 Sep 2025
Contributed by Lukas
Merck's announcement that it is moving its R&D out of the U.K. highlights concerns about the country’s life sciences policies. On the lates...
Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more
09 Sep 2025
Contributed by Lukas
Molecular biologist and Nobel Prize winner David Baltimore made foundational contributions to the biopharma industry and was the essential figure behi...
Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines
03 Sep 2025
Contributed by Lukas
Two veteran biotech leaders are launching a new company with ambitions in the cardiovascular disease space. On the latest BioCentury This Week podcast...
Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat
26 Aug 2025
Contributed by Lukas
There’s been a rare IPO filing on NASDAQ as LB Pharma looks to test the market during a year that has seen little activity among U.S. biotechs even ...
Ep. 316 - Trends in Pharma Deals
19 Aug 2025
Contributed by Lukas
BioCentury’s third annual analysis of pharma company deals finds that bispecifics and degraders are in, cell and gene therapies are out, and China i...
Ep. 315 - China Speed: Data, Deals, First in Class
14 Aug 2025
Contributed by Lukas
Dealmaking between Western and Chinese biopharmas has been one of the year’s bright spots, as a maturing biotech landscape in China converges with W...
Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure
12 Aug 2025
Contributed by Lukas
Phase III data from Lilly’s orforglipron in obesity fell short of investor expectations, but they appear to be enough to obtain approval and wide us...
Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer
05 Aug 2025
Contributed by Lukas
The ouster of Vinay Prasad after three months running FDA’s Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On ...
Ep. 312 - Biotech Progress Report
30 Jul 2025
Contributed by Lukas
A handful of encouraging signals is cause for cautious optimism for biotech headed into the second half of the year — companies have been able to pa...
Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More
29 Jul 2025
Contributed by Lukas
This week’s deal between GSK and Jiangsu Hengrui is a prime example of how Western biopharmas have begun to recognize the innovation and opportuniti...
Ep. 310 - Sarepta & What's Next for Gene Therapy. Plus: Leading FDA's CDER
22 Jul 2025
Contributed by Lukas
Last week’s public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene...
Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days
14 Jul 2025
Contributed by Lukas
Chinese biotech is the lone bright spot for the biopharma financial markets in 1H25, as macro concerns about the most favored nation (MFN) pricing pol...
Ep. 308 - Grand Rounds - Europe Preview
09 Jul 2025
Contributed by Lukas
There are many reasons why it may be the European biomedical ecosystem’s moment to shine, and advances at the academia-industry interface are a core...
Ep. 307 - How Cancer Regulation is — and isn’t — Changing at FDA
08 Jul 2025
Contributed by Lukas
Oncology regulation has been less affected by recent changes in FDA leadership than other parts of the agency. On a special sponsored edition of the B...
Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences
08 Jul 2025
Contributed by Lukas
Treg-based cell therapies are nearing a clinical proof-of-concept inflection point, but in an environment that has dramatically shifted with the adven...
Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2
01 Jul 2025
Contributed by Lukas
The Trump administration’s overhaul of FDA is still underway, but the agency has already veered away from its decades-long trajectory in ways that w...
Ep. 304 - Syncona Reshapes Fund; Lilly's $1B Verve Bet; FDA's 2-Track Future
24 Jun 2025
Contributed by Lukas
Publicly traded U.K. investment firm and company builder Syncona is restructuring its fund amid ongoing market challenges in the biopharma industry. O...
Ep. 303 - Gene Therapy Safety, Amylin in Obesity & FDA's Future
16 Jun 2025
Contributed by Lukas
The tragic death of a second non-ambulatory DMD patient treated with Sarepta's Elevidys gene therapy marks a turning point for the field and shou...
Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago
12 Jun 2025
Contributed by Lukas
With federal funding at risk and VCs increasingly focused on de-risked assets, academia is facing unprecedented headwinds despite rapid advancements i...
Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans
10 Jun 2025
Contributed by Lukas
Translational trends at this year’s ASCO meeting featured new and selective ways to target cell surface receptors on solid tumors. On the latest Bio...
Ep. 300 - Biotech’s $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat
03 Jun 2025
Contributed by Lukas
Dealmaking by a pair of pharmas has given the biotech industry its best day of transactions in months, tallying nearly $13 billion in guaranteed payme...
Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs
28 May 2025
Contributed by Lukas
Dutch biotech Merus’ EGFR x LGR5 bispecific antibody has caught investors’ attention in the run-up to ASCO as a new approach to block EGFR signali...
Ep. 298 - Takeaways from the 25th Bio€quity Europe
23 May 2025
Contributed by Lukas
Political and market turmoil has raised questions whether the U.S. can retain its biopharma leadership position, and in turn presents Europe with an o...
Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO
20 May 2025
Contributed by Lukas
The turbulence that has come with the Trump administration’s policies related to the U.S. biopharmaceutical industry is creating an opening for Euro...
Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights
13 May 2025
Contributed by Lukas
Biopharmas developing therapies for obesity are looking to a future where the quality of weight loss matters as much as the quantity — what targets ...
Ep. 295 - Bio€quity Europe 2025 Preview
09 May 2025
Contributed by Lukas
This year’s Bio€quity Europe conference — the 25th edition of the event — will focus on what’s next for Europe amid biotech’s current comp...
Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing
06 May 2025
Contributed by Lukas
Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid ...
Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs
29 Apr 2025
Contributed by Lukas
Belief in tau — both as a target and surrogate endpoint — for Alzheimer’s is building among leaders in the field. On the latest BioCentury This ...
Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview
26 Apr 2025
Contributed by Lukas
Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare aut...
Ep. 291 - Grand Rounds - U.S. Preview
25 Apr 2025
Contributed by Lukas
The academia-industry interface is more important than ever for sustaining biomedical innovation’s forward momentum, even as the Trump administratio...
Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed
22 Apr 2025
Contributed by Lukas
The biotech community is reeling, fearful and furious about the fallout of tariff, FDA and NIH policies, according to BioCentury’s newly released Ri...
Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA
15 Apr 2025
Contributed by Lukas
FDA’s plan to move away from animal toxicity testing could expedite INDs and cut costs for biopharma companies, while helping the U.S. maintain its ...
Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview
08 Apr 2025
Contributed by Lukas
Loss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent macroeconomic climate...
Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI
01 Apr 2025
Contributed by Lukas
Biotech indexes are tumbling after one of FDA’s last veteran leaders was pushed out by HHS Secretary RFK Jr. and the threat of tariffs weigh on a ke...
Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs
25 Mar 2025
Contributed by Lukas
European venture firm Sofinnova Partners is expanding the reach of its Biovelocita accelerator beyond Italy to stretch across the greater continent. O...
Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play
18 Mar 2025
Contributed by Lukas
BIO is engaging with President Donald Trump to protect and improve FDA. It’s also hoping biopharmas can dodge tariffs and find paths to modify the I...
Ep. 284 - Takeaways from the East-West Summit
12 Mar 2025
Contributed by Lukas
While the culling of companies in the biotech bear market may have yet to subside, creative cross-border deal-making on innovative assets is spreading...
Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI
11 Mar 2025
Contributed by Lukas
The almost certain confirmation of Marty Makary as FDA commissioner this month will cap a transition marked by internal upheaval and political infight...
Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity
04 Mar 2025
Contributed by Lukas
The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform c...
Ep. 281 - Roche Reboot and 5 Things on Trump 2.0
25 Feb 2025
Contributed by Lukas
Once pharma’s oncology powerhouse, Roche is charting a new course that extends beyond its traditional stronghold in cancer therapeutics. On the late...
Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs
19 Feb 2025
Contributed by Lukas
Rather than fretting over increasing competition from Chinese life sciences companies, biotechs in the U.S. should rise to the challenge and learn fro...
Ep. 279 - East-West Summit Preview
15 Feb 2025
Contributed by Lukas
Western VCs are paying more attention than ever to innovation emerging from Asia — from antibody-drug conjugates to bispecifics, AI and beyond — a...
Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine
11 Feb 2025
Contributed by Lukas
White House plans to slash FDA and NIH risk decimating two agencies at the core of U.S. biomedical innovation. On the latest BioCentury This Week podc...
Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug
04 Feb 2025
Contributed by Lukas
The boom in the creation of companies that were launched in the West based on assets sourced in Asia signals China’s galloping speed of innovation. ...
Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler
31 Jan 2025
Contributed by Lukas
Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals' $14 billion takeout by Bristol My...
Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH
28 Jan 2025
Contributed by Lukas
BioCentury’s analysis of the technologies behind last year’s biotech series A raisers sees progress in nanoparticles, CAR cell therapies, degrader...
Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI
22 Jan 2025
Contributed by Lukas
With political uncertainty overshadowing market sentiment going into 2025, BioCentury’s editorial team assesses the bull and bear arguments for biot...
Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds
17 Jan 2025
Contributed by Lukas
Sunshine and a stream of deals brightened the mood at this year’s J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued p...
Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma
13 Jan 2025
Contributed by Lukas
J&J’s $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a...
Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure
07 Jan 2025
Contributed by Lukas
Can biotech break free of the macro factors that have buffeted the industry of late? On the first BioCentury This Week podcast of 2025, BioCentury’s...
Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data
30 Dec 2024
Contributed by Lukas
Preview: In his five decades at FDA, Robert “Bob” Temple helped revolutionize the ways medical products are developed and regulated. On the latest...
Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
23 Dec 2024
Contributed by Lukas
With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their c...
Ep. 269 - Trends in VC Funds, Obesity Start-ups and More
17 Dec 2024
Contributed by Lukas
Lately, it appears some biotech VCs have hit a ceiling, capping their new funds at or below the amount of their previous vehicles, says Paul Bonanos o...
Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal
10 Dec 2024
Contributed by Lukas
A pair of lawmakers have dealt the Biosecure Act a setback that could derail the legislation, even as Congress continues its push to reduce reliance o...
Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts
03 Dec 2024
Contributed by Lukas
On the latest BioCentury This Week podcast, Washington Editor Steve Usdin and colleagues discuss how President-elect Donald Trump’s pick to lead NIH...
Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update
26 Nov 2024
Contributed by Lukas
Positive vibes about biotech emanating from the Jefferies Healthcare Conference were overshadowed by the uncertainty that is ahead because of the resu...
Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals
19 Nov 2024
Contributed by Lukas
Giving RFK Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding on his E...
Ep. 264 - Prepping for Trump & Alzheimer's Ethics
12 Nov 2024
Contributed by Lukas
Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest Bi...
Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser
05 Nov 2024
Contributed by Lukas
It’s too soon to conclude anti-amyloid therapies are safe for use by Alzheimer’s patients in the real world, even as early reports are encouraging...
Ep. 262 - EGFR Case Study, FDA & Politics
29 Oct 2024
Contributed by Lukas
Twenty years of innovation in therapies targeting EGFR provides a case study in how generation of differentiated products against the target can drive...
Ep. 261 - China Summit: Reinventing Your China Strategy
24 Oct 2024
Contributed by Lukas
Cross-border geopolitical tensions and a prolonged capital crunch are compelling biopharma companies from Beijing to Boston to rethink their strategie...
Ep. 260 - VC Funds, New Chapter for MS, Wave's Data
22 Oct 2024
Contributed by Lukas
At least 25 venture firms have raised a total of more than $17 billion in funds this year, with Forbion unveiling the largest-ever European biopharma ...
Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA
15 Oct 2024
Contributed by Lukas
There is a growing mandate among researchers and VCs to provide proof of causal human biology for new targets. On the latest BioCentury This Week podc...
Ep. 258 - Breaking the Bear: 4Q Public Markets Preview
08 Oct 2024
Contributed by Lukas
Biopharma buysiders and bankers at long last believe the conditions are ripe for biotech growth and outperformance, BioCentury’s Stephen Hansen says...
Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update
01 Oct 2024
Contributed by Lukas
Approval of BMS’s first-in-class schizophrenia drug is good news for patients and the company’s thinning pipeline alike, but maximizing Cobenfy’...
Ep. 256 - ESMO Recap: Keeping TIGIT Alive, Rybrevant & Immunotherapy Anniversary
26 Sep 2024
Contributed by Lukas
The ESMO Congress yielded another win for cancer immunotherapy target TIGIT, but the readout resurfaced worries about the mechanism’s past failures ...
Ep. 255 - Pediatric PRVs, Biosecure & Novo's Obesity Miss
24 Sep 2024
Contributed by Lukas
Rep. Frank Pallone’s misunderstanding of how the pediatric priority review voucher program works has been one factor undermining support for an ince...
Ep. 254 - Takeaways from Grand Rounds 2024
20 Sep 2024
Contributed by Lukas
On a special edition of the BioCentury This Week podcast, BioCentury’s editors deliver their takeaways from the debut Grand Rounds conference, which...
Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech
17 Sep 2024
Contributed by Lukas
On the latest BioCentury This Week podcast, BioCentury’s editors assess the shifting market for biotech IPOs, including the profiles of the three co...
Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset
10 Sep 2024
Contributed by Lukas
Will bispecifics be the drugs to dethrone cancer’s biggest blockbusters? Akeso is the latest company with a bispecific to impress in a head-to-head ...
Ep. 251 - Eyes on the target: a Back to School Overview
07 Sep 2024
Contributed by Lukas
In this year’s series of Back to School essays, BioCentury’s editors ask whether the era of human first, causal biology and personalized medicine ...
Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery
04 Sep 2024
Contributed by Lukas
A vote on the Biosecure Act in the U.S. House of Representatives early next week shines the spotlight back on legislation seeking to rein in Chinese C...
Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update
27 Aug 2024
Contributed by Lukas
Shaking up an underwhelming year for fresh biotech paper, a trio of biotechs filed to go public on NASDAQ last week. On the latest BioCentury This Wee...
Ep. 248 - Grand Rounds Preview: Eyes on the Target
23 Aug 2024
Contributed by Lukas
Grand Rounds is an R&D meeting that represents BioCentury’s latest initiative to create new networks linking academic discoveries with translati...
Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School
20 Aug 2024
Contributed by Lukas
The Biden administration has disclosed what Medicare will pay for the first graduates of its drug price negotiation program but biopharma companies, b...
Ep. 246 - Wilson’s Vision for Gene Therapy. Plus: Korea Biotech & Grand Rounds
13 Aug 2024
Contributed by Lukas
Pharmaceutical companies and some investors may have once again become wary of gene therapy, but the modality’s future is bright, according to Jim W...
Ep. 245 - Biotech-Academia Deals, Leqembi's Latest, Wilson Moves On
06 Aug 2024
Contributed by Lukas
A substantial part of the biopharma ecosystem involves deals between biotechs and academics, with smaller companies accessing assets to add to their p...
Ep. 244 - Leqembi's Thumbs-Down in Europe. Plus: Perioperative Cancer, Pediatric Review Vouchers
30 Jul 2024
Contributed by Lukas
Europe’s CHMP has again ruled in contrast to FDA for a neurology product, this time on Biogen and Eisai’s Leqembi for Alzheimer’s disease. On th...
Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs
23 Jul 2024
Contributed by Lukas
Alpha emitters are the latest trend in the hot radioligand space, but there’s debate about which isotope offers the best attributes for optimizing s...